The Journal of Membrane Biology ( IF 2.3 ) Pub Date : 2021-07-23 , DOI: 10.1007/s00232-021-00192-z Jiang Liu 1 , Jiang Tian 1 , Komal Sodhi 2 , Joseph I Shapiro 3
|
In different large-scale clinic outcome trials, sodium (Na+)/glucose co-transporter 2 (SGLT2) inhibitors showed profound cardiac- and renal-protective effects, making them revolutionary treatments for heart failure and kidney disease. Different theories are proposed according to the emerging protective effects other than the original purpose of glucose-lowering in diabetic patients. As the ATP-dependent primary ion transporter providing the Na+ gradient to drive other Na+-dependent transporters, the possible role of the sodium–potassium adenosine triphosphatase (Na/K-ATPase) as the primary ion transporter and its signaling function is not explored.
Graphic Abstract
中文翻译：
Na/K-ATPase 信号传导和 SGLT2 抑制剂介导的心脏保护：交叉路口？
在不同的大规模临床结果试验中，钠 (Na + )/葡萄糖协同转运蛋白 2 (SGLT2) 抑制剂显示出显着的心脏和肾脏保护作用，使其成为心力衰竭和肾脏疾病的革命性治疗方法。除了糖尿病患者降糖的最初目的之外，根据新出现的保护作用提出了不同的理论。由于 ATP 依赖性初级离子转运体提供 Na +梯度以驱动其他 Na +依赖性转运体，钠-钾腺苷三磷酸酶 (Na/K-ATPase) 作为初级离子转运体及其信号传导功能的可能作用不是探索了。
京公网安备 11010802027423号